Form 4: Dexcom CEO Kevin Sayer Disposes of Shares Under 10b5-1 Plan
SEC Form 4 Filing
Dexcom's CEO, Kevin Sayer, sold shares of common stock on April 8, 2024, under a pre-arranged 10b5-1 trading plan.
Summary
- On April 8, 2024, Kevin R Sayer, the President, CEO, and Chairman of Dexcom Inc, sold shares of Dexcom's common stock.
- The sales were executed under a 10b5-1 plan adopted on December 12, 2023, allowing for the orderly disposition of shares.
- Two transactions occurred: the first involved the sale of 27,272 shares at a weighted average price of $137.9616, and the second involved the sale of 22,361 shares at a weighted average price of $138.7079.
- Following these transactions, Sayer directly owns 283,893 shares of Dexcom common stock.
- This number includes 109,641 unvested restricted stock units, which vest through March 8, 2027, March 8, 2026 and March 8, 2025.
Sentiment
Score: 5
Explanation: The sentiment is neutral as the document simply reports transactions under a pre-existing plan. There is no indication of positive or negative implications for the company's performance.
Risks
- Sales by insiders, even under pre-arranged plans, can sometimes be perceived negatively by the market.
Industry Context
Insider sales are a common occurrence in publicly traded companies, often executed under pre-arranged trading plans like the 10b5-1 plan to avoid accusations of trading on non-public information. These plans allow insiders to sell shares at predetermined times and prices.
Comparison to Industry Standards
- It's common for executives at publicly traded companies like Dexcom (DXCM) to utilize 10b5-1 plans for managing their stock sales.
- Comparable companies such as Abbott (ABT) and Medtronic (MDT) also see similar insider trading activity under these plans.
- The volume and frequency of these sales are generally in line with industry practices for executive compensation and diversification strategies.
Stakeholder Impact
- The impact on stakeholders is likely minimal, as the sales were conducted under a pre-arranged plan and represent a small fraction of the company's outstanding shares.
Key Dates
| Date | Description |
|---|---|
| 12/12/2023 | Mr. Sayer adopted a 10b5-1 Plan |
| 03/08/2024 | Grant date of 51,692 unvested restricted stock units, vesting through March 8, 2027 |
| 03/09/2023 | Grant date of 36,281 unvested restricted stock units, vesting through March 8, 2026 |
| 03/08/2022 | Grant date of 21,668 unvested restricted stock units, vesting through March 8, 2025 |
| 04/08/2024 | Date of stock sale transactions |
| 04/10/2024 | Date of Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.